Cytomegalovirus Vaccine for Cytomegalovirus

Palo Alto (17 mi)

Age: < 65

Sex: Any

Travel: May be covered

Time Reimbursement: Varies

Trial Phase: Phase 1 & 2

Waitlist Available

Sponsor: ModernaTX, Inc.

Trial Summary

What is the purpose of this trial?This trial tests the safety and effectiveness of the mRNA-1647 vaccine in healthy young people and older females. The vaccine helps the body recognize and fight CMV by teaching it to produce a harmless piece of the virus.

Eligibility Criteria

Inclusion Criteria

Are you pregnant?

How old is the person who wants to participate?

The study is only open to certain genders.

You do not have any underlying health conditions and are generally healthy.

Can you commit to attending about 12 study visits over a period of 18 months?

You have received a COVID-19 vaccine or participated in a clinical trial within the past month.

Treatment Details

5Treatment groups

Experimental Treatment

Placebo Group

Group I: mRNA-1647 Dose CExperimental Treatment1 Intervention

CMV-seronegative or CMV-seropositive participants 9 to 15 years of age and 16 to 25 years of age will receive mRNA-1647 at Dose Level C by IM injection given as a 3-injection series on Day 1, Month 2, and Month 6.

Group II: mRNA-1647 Dose BExperimental Treatment1 Intervention

CMV-seronegative or CMV-seropositive participants 9 to 15 years of age will receive mRNA-1647 at Dose Level B by IM injection given as a 3-injection series on Day 1, Month 2, and Month 6.

Group III: mRNA-1647 Dose AExperimental Treatment1 Intervention

CMV-seronegative or CMV-seropositive participants 9 to 15 years of age will receive mRNA-1647 at Dose Level A by intramuscular (IM) injection given as a 3-injection series on Day 1, Month 2, and Month 6.

Group IV: Dose Expansion: mRNA-1647Experimental Treatment1 Intervention

CMV-seronegative or CMV-seropositive participants 9 to 15 years of age will receive mRNA-1647 at selected dose level by IM injection given as a 3-injection series on Day 1, Month 2, and Month 6.

Group V: Dose Expansion: PlaceboPlacebo Group1 Intervention

Participants will receive placebo by IM injection given as a 3-injection series on Day 1, Month 2, and Month 6.